- Study designed to determine differential diagnosis in depression patients
- Study designed to monitor patient data following pharmacological treatment
SYDNEY, Australia and MINNEAPOLIS, Dec. 14, 2017 -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions, is pleased to announce the first prospective clinical trial with Mayo Clinic under a 5-year Master Clinical Trial Agreement that was signed in October of this year. This initial study, undertakes the prospective diagnosis and longitudinal monitoring of both unipolar and bipolar depression, along with the depressive subtypes (melancholic and atypical).
The primary goal is to characterize longitudinal autonomic, circadian, and sleep patterns, as classified by the Medibio Analytics Platform (MAP), following the initiation of a standard pharmacological treatment for a new or recurrent, moderate-to-severe major depressive episode of both the unipolar and bipolar type. Additionally, MAP will be used to characterize patterns unique to the bipolar type depression.
The research study team will be led by Mark A. Frye, M.D., at Mayo Clinic’s Rochester campus. Dr. Frye, the chair of Mayo’s Department of Psychiatry and Psychology, received his medical degree from the University of Minnesota and completed his psychiatric training at the UCLA Neuropsychiatric Institute. He completed a subsequent research fellowship in the Biological Psychiatry Branch at the National Institute of Mental Health (NIMH) in Bethesda, Maryland. While at NIMH, his area of research was focusing on the neurobiology of depression and bipolar disorder.
“We have been eager to get this initial study started with Dr. Frye and Mayo Clinic, as this kicks off our first of many collaborations in mental health between our organizations. The importance of this study is to look at bipolar depression and differential diagnosis with our analytics platform, which can ultimately drive getting the right treatment to the right patient at the right time. Mayo remains a leading academic center of excellence that the world looks to for innovative solutions to global problems,” says Jack Cosentino, Medibio’s CEO and Managing Director.
”The Mayo Clinic Depression Center has focused our research efforts on studies that have the potential to innovate our clinical practice; making a positive impact on patients’ lives,” says Dr. Frye.
It is estimated that 350M people worldwide suffer from depression. Depression is one of the leading causes of disability in the United States. Two major challenges in the clinical practice of mood disorder is distinguishing major depressive disorder from bipolar depression and individualizing treatments for patients who struggle with depression. As treatment options markedly differ in these two mood disorders, biomarkers to help accurate diagnosis and guide treatment would be of tremendous clinical value.
About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.
Further Information: Website: www.medibio.com.au Medibio Shareholder Enquiries: Jack Cosentino CEO and Managing Director Medibio Limited [email protected] T: +1 (952) 465 4787 Australian Media Enquiries: Peter Taylor NWR Communications [email protected] T: +61 (0) 412 036 231


American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Washington Post Publisher Will Lewis Steps Down After Layoffs
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Instagram Outage Disrupts Thousands of U.S. Users
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 



